Trillium Therapeutics (TRIL) Presents Data on TTI-621 in Blocking CD47 'Do Not Eat' Signal

September 26, 2016 5:23 PM EDT
Get Alerts TRIL Hot Sheet
Trade TRIL Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Trillium Therapeutics (NASDAQ: TRIL) presents data on TTI-621 (SIRPαFc) in blocking CD47 "do not eat" signal today. Key points from the presentation (which is embedded below):

  • CD47 binds to SIRPo on the surface of macrophages and delivers a "do not eat" signal to suppress phagocytosis
  • Tumor cells frequently overexpress CD47 and exploit this pathway to evade macrophage-mediated destruction
  • Blocking CD47 using TTI-621, a soluble SIRPαFc decoy receptor fused to a human IgG1, neutralizes the suppressive effects of CD47 and triggers macrophage-mediated phagocytosis of tumor cells in vitro, and effectively controls tumor growth in vivo
  • In this study we have investigated whether TTI-621-mediated phagocytosis results in augmented T cell responses
  • To evaluate the T cell response to a model tumor antigen, Jurkat (a human leukemia cell line) was stably transfected with a construct containing the human cytomegalovirus phosphoprotein pp65 (CMVJurkat)
  • Macrophages that had phagocytosed CMV-Jurkat in the presence of TTI-621 were assessed for their ability to present tumor antigen and subsequently trigger tumor-specific autologous CD8+ T cell responses

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, FDA

Add Your Comment